GlassScriptPhysician profile
Carlos Midence
NPI 1073502753
$7,062.84
in general payments reported to CMS, 2019-2025
48 companies · $559 in 2025
The $559 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,027 · 2020: $2,443 · 2021: $284 · 2022: $600 · 2023: $150 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $956.43 | 2019-2025 | Keytruda, Welireg |
| Rigel Pharmaceuticals, INC. | $776.03 | 2019-2025 | Tavalisse, Rezlidhia, Gavreto |
| Janssen Biotech, INC. | $697.61 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Novartis Pharmaceuticals Corporation | $619.63 | 2019-2022 | |
| Celgene Corporation | $462.46 | 2019-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $422.24 | 2019-2022 | |
| Incyte Corporation | $348.79 | 2019-2022 | |
| Pfizer INC. | $224.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $224.32 | 2019-2020 | |
| Genentech USA, INC. | $175.75 | 2019-2022 | |
| Astellas Pharma US INC | $151.39 | 2019-2025 | Xospata, Padcev |
| Eisai INC. | $149.93 | 2019-2025 | |
| Clovis Oncology, INC. | $144.87 | 2019-2020 | |
| Emd Serono, INC. | $139.05 | 2019-2020 | |
| Amgen INC. | $129.59 | 2019-2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Midence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.